The present invention relates to the new use of the compound 3-(1′-adamantyl)-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzopyran for the treatment of diseases or conditions that are associated with β-amyloid induced toxicity, such as Alzheimers disease.